Kodiak Sciences Inc.
35.00%
22,049,297
1468748
Sep 27, 2026
Sep 30, 2026, 04:39 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | Investment Adviser | 35.00% | 22,049,297 | 22,049,297 | 0 |
| Baker Bros. Advisors (GP) LLC | Holding Company | 35.00% | 22,049,297 | 22,049,297 | 0 |
| Julian C. Baker | Individual | 35.00% | 22,049,297 | 22,049,297 | 0 |
| Felix J. Baker | Individual | 35.00% | 22,049,297 | 22,049,297 | 0 |
Disclosure Items (5)
Common Stock, $0.0001 par value per share
Kodiak Sciences Inc.
1250 Page Mill Road, Palo Alto, CA, 94304
Item 3 of Schedule 13D is supplemented and amended, as the case may be, as follows: The disclosure in Item 5 below is incorporated herein by reference.
The disclosures in the Reporting Persons' cover pages and in Item 4 are incorporated by reference herein. Items 7 through 11 and 13 of each of the cover pages of this Amendment No. 12 are incorporated herein by reference. The percentage of beneficial ownership for each of the Reporting Persons reported herein is based on 62,849,457 shares of Common Stock outstanding as of August 6, 2026 as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission ("SEC") on August 13, 2026 plus 188,356 vested non-qualified options exercisable for 188,356 shares of Common Stock ("Stock Options") received by Felix J. Baker as compensation for his service on the Board. Set forth in Exhibit 99.1 is the aggregate number of shares of Common Stock directly held by each of the Funds, which may be deemed to be indirectly beneficially owned by the Reporting Persons along with the percentage of Common Stock held by each of the Funds.
Items 7 through 10 of each of the cover pages of this Amendment No. 12 are incorporated herein by reference. The disclosure in Item 5(a) is incorporated herein by reference. The direct holdings of the Funds are detailed in Exhibit 99.1, which is incorporated herein by reference. Felix J. Baker, a managing member of the Adviser GP, currently serves on the Board. He is Chair of the Compensation Committee and serves on the Nominating/Governance Committee. Felix J. Baker, as compensation for his service on the Board, receives Stock Options. Felix J. Baker holds 24,747 vested Stock Options that have an exercise price of $10.13 per share expiring June 2, 2029, 4,135 vested Stock Options that have an exercise price of $62.50 per share expiring June 7, 2030, 7,106 vested Stock Options that have an exercise price of $54.12 per share expiring June 29, 2030, 7,368 vested Stock Options that have an exercise price of $93.00 per share expiring June 29, 2031, 25,000 vested Stock Options that have an exercise price of $7.64 per share expiring June 29, 2032, 40,000 vested Stock Options that have an exercise price of $6.90 per share expiring June 29, 2033, 40,000 vested Stock Options that have an exercise price of $2.35 per share expiring June 27, 2034, 40,000 vested Stock Options that have an exercise price of $3.73 per share expiring June 29, 2035, and 17,731 options to purchase 17,731 shares of Common Stock which were granted on June 30, 2026, that have an exercise price of $38.96 per share expiring June 29, 2036, which will vest on the earlier of June 30, 2027 or one day prior to the next annual meeting of the Issuer's stockholders. The policies of the Funds and the Adviser do not permit managing members of the Adviser GP to receive compensation for serving as a director of the Issuer, and the Funds are instead entitled to the pecuniary interest in any compensation received for Felix J. Baker's service on the Board. The Adviser, the Adviser GP, and Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of the Stock Options held by Felix J. Baker disclosed herein and in previous amendments to this Schedule 13D. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.
The transactions in Common Stock detailed in Exhibit 99.2 were effected by the Adviser on behalf of the Funds during the sixty days preceding the filing of this statement. All transactions were effected in the over-the-counter market directly with a broker-dealer. Except as disclosed herein, none of the Reporting Persons or their affiliates has effected any other transactions in securities of the Issuer during the past sixty days.
Certain securities of the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the managing members of Baker Biotech Capital (GP), LLC. Certain securities of the Issuer are held directly by Life Sciences, a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the managing members of Baker Brothers Life Sciences Capital (GP), LLC.
Not applicable.
99.1 Holding by the Funds in Securities of the Issuer 99.2 Item 5(c) Transactions in Common Stock